a day ago
Groundbreaking Cold Plasma technology introduced in Oman
Muscat — A major leap in advanced wound care and infection management was marked this week with the official launch of the Neoplas Argon Jet Cold Plasma device in Oman. The CE MDR-approved German technology was introduced by Alfarsi National Enterprises following successful clinical evaluations at Khoula Hospital and Oman International Hospital.
To commemorate the launch, a high-profile medical symposium was held in Muscat, drawing the participation of over 150 doctors and healthcare professionals from across the country. The event brought together leading experts from Europe and Oman for a full day of scientific exchange, practical insight, and a live demonstration of the device.
The Neoplas Argon Jet utilizes cold atmospheric argon plasma to accelerate wound healing, stimulate tissue regeneration, and inactivate pathogens — without pain or other side effects. Its use in treating diabetic foot ulcers, chronic wounds, dermatological lesions, and post-surgical infections has already shown remarkable results in clinical settings.
'This is more than a product launch; it's the beginning of a new chapter in how we approach wound care in Oman,' said Saju George, Managing Director of Alfarsi National Enterprises. 'The clinical success at top hospitals and the overwhelming interest from the medical community show just how timely and impactful this technology is.'
The Neoplas Argon Jet is the result of years of rigorous scientific collaboration involving neoplas med GmbH, the Leibniz Institute for Plasma Science and Technology (INP), University Medical Center Greifswald, Charité – Universitätsmedizin Berlin, and various research and industrial partners across Europe.
The symposium featured renowned speakers including Dr. Christian Seebauer, a pioneer in plasma-based wound care from Germany; Dr. Aleksandra Szlachcic, a Polish dermatologist with years of clinical experience in scar and dermatological treatments; and Prof. Dr. Ralf Lobmann, a leading diabetologist specializing in diabetic foot ulcers. Dr. Klaus Ruhnau, COO of Neoplas Med GmbH, also addressed the audience, highlighting the global momentum behind cold plasma therapy.
'This symposium brought science, practice, and future potential together in one place,' said Dr. Ruhnau. 'We were thrilled to see the level of engagement and curiosity from Oman's medical professionals.'
Throughout the day, attendees explored the underlying science of cold plasma, its medical and economic impact, and its potential to transform the treatment of complex wounds. Sessions highlighted growing global evidence for PlasmaJet technology and its applications in dermatology and infection control. The event also featured a live demonstration and hands-on experience, allowing participants to observe and practice using the system in a simulated clinical environment.
With its robust scientific backing, and growing international recognition, the Neoplas Argon Jet is now available in Oman — offering a safe, effective, and non-antibiotic treatment solution for some of the most challenging wound care cases in modern medicine.
